收购后关系资产的剥离:来自生物制药行业的证据

Divestment of relational assets following acquisitions: Evidence from the biopharmaceutical industry

STRATEGIC MANAGEMENT JOURNAL · 2022
被引 18
人大 AFT50UTD24ABS 4*

中文导读

研究发现收购会提高联盟终止的可能性,尤其是当收购方管理能力不足或继承目标公司联盟时,这提醒管理者在评估收购时要考虑联盟稳定性风险。

Abstract

Abstract Research Summary We examine whether acquisitions affect the divestment of firms' alliance‐based relational assets. Using data from the biopharmaceutical industry and a matched case–control research design, we find that alliances are more likely to be terminated following acquisitions compared to alliances not subject to acquisitions. This higher termination likelihood is driven by acquisitions where the acquirer's alliance management capacity is stressed, and by alliances inherited from targets. The inherited alliance effect is attenuated by the target's partner's common connections with the acquirer but amplified by the target's partner's unique connections outside the merging firms' alliance portfolios. These findings are consistent with our relational view‐based theorizing on the post‐acquisition challenges of retaining alliance‐based assets, contributing to corporate strategy scholarship on alliances and acquisitions. Managerial Summary In many industries, firms' portfolios of interorganizational alliances enable them to realize novel complementarities and, thereby, enhance their performance. In such sectors, managers also frequently acquire other organizations to obtain access to critical resources. However, what managers may overlook is that acquisitions can destabilize existing alliance relationships. In this study, we show that the acquiring firm's capacity to effectively manage alliance‐based assets is stressed once it inherits the target firm's alliances. In general, target firm alliances become more challenging to sustain, and, in particular, those that hold a higher potential for novelty become more unstable. Consequently, when evaluating acquisitions, managers should look beyond obvious measures of a target alliance's value and assess the post‐acquisition integration challenges that may threaten its stability.

并购联盟生物制药企业战略